Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02022787 | Value of Various Chemokines in the Detection and Follow up of RCC | unknown | — | 30 | Carmel Medical CenterOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00788060 | A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma(Rad/Sutent) | completed | Phase 1 | 5 | Daniel George, MDOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01791387 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC(DILIGENCE-1) | unknown | Phase 2 | 30 | Auckland District Health BoardOTHER_GOV | 1 | Feb 3, 2015 | clinicaltrials |
| NCT01353794 | Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer(POWER-NEXT) | withdrawn | — | 0 | BayerINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT01508364 | Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma(NEXTAR) | completed | — | 20 | BayerINDUSTRY | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00126503 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | terminated | Phase 4 | 2 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00661375 | BAY43-9006 Phase II Study for Renal Cell Carcinoma | completed | Phase 2 | 131 | BayerINDUSTRY | 1 | Dec 25, 2014 | clinicaltrials |
| NCT02324803 | Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | unknown | Phase 2 | 86 | Southern China Urology Cancer ConsortiumOTHER | 1 | Dec 24, 2014 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01034878 | Sunitinib in Metastatic Renal Cancer | completed | Phase 2 | 25 | Istituto Clinico HumanitasOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00044564 | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 54 | BayerINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | completed | Phase 2 | 501 | BayerINDUSTRY | 2 | Dec 19, 2014 | clinicaltrials |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | terminated | Phase 1 | 12 | BayerINDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01015911 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | completed | Phase 1 | 58 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01274273 | Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer | unknown | Phase 2 | 118 | University of AarhusOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01967407 | IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.(IRENE) | unknown | Phase 1 / Phase 2 | 20 | University of MagdeburgOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00520403 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | completed | Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00570882 | Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 76 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT02247583 | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment(IPSOC) | completed | — | 90 | KU LeuvenOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01405183 | Association Between Hepatitis C Infection and Renal Cell Carcinoma | completed | — | 240 | Henry Ford Health SystemOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00056537 | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer | completed | Phase 1 | 44 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT00384969 | Sorafenib and RAD001 Renal Cell Carcinoma | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT01838720 | Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage | unknown | N/A | 90 | RenJi HospitalOTHER | 1 | Aug 13, 2014 | clinicaltrials |
| NCT00111020 | Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma | completed | Phase 3 | 2,567 | BayerINDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT02208128 | Molecular Determinants for Therapy Response on Renal Cell Carcinoma(MORE) | unknown | N/A | 4 | Heidelberg UniversityOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT01408004 | Rotating Pazopanib and Everolimus to Avoid Resistance(ROPETAR) | completed | Phase 2 | 101 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00265135 | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 68 | Centocor, Inc.INDUSTRY | 4 | Jul 3, 2014 | clinicaltrials |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00515697 | A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00918281 | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection | completed | Phase 2 | 70 | GE HealthcareINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT01198184 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01473043 | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | no longer available | — | — | PfizerINDUSTRY | 2 | May 30, 2014 | clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2015source: clinicaltrials